SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A

Psychiatric Genetics

Volumn 19, Issue 6, 2009, Pages 281-291

  Villafuerte, Sandra M ^a,b   Vallabhaneni, Kamala ^a   Śliwerska, Elzbieta ^a   McMahon, Francis J ^d   Young, Elizabeth A ^a,b   Burmeister, Margit ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Association; Depression; Haplotype; HTR1A; HTR1B; Selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALLELE; ARTICLE; DESENSITIZATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

DEPRESSION; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN UPTAKE INHIBITORS;

EID: 70350749513     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e32832a506e     Document Type: Article

References (60)

1. Abecasis GR, Cookson WO (2000). GOLD - graphical overview of linkage disequilibrium. Bioinformatics 16:182-183.
2. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L (2003). 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23:563-567.
3. Artigas F, Perez V, Alvarez E (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51:248-251.
4. Ballesteros J, Callado LF (2004). Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79:137-147.
5. Baskaran N, Kandpal RP, Bhargava AK, Glynn MW, Bale A, Weissman SM (1996). Uniform amplification of a mixture of deoxyribonucleic acids with varying GC content. Genome Res 6:633-638.
6. Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. (1999). The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 45:1170-1177.
7. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS (1997). Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154:37-43.
8. Binder EB, Salyakina D, Lichtner P,Wochnik GM, Ising M, Putz B, et al. (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319-1325.
9. Blier P, Bergeron R (1995). Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15:217-222.
10. Duan J, Sanders AR, Molen JE, Martinolich L, Mowry BJ, Levinson DF, et al. (2003). Polymorphisms in the 50-untranslated region of the human serotonin receptor 1B (HTR1B) gene affect gene expression. Mol Psychiatry 8:901-910.
11. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30:1269-1277.
12. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, et al. (1996). Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 97:614-619.
13. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457-494.
14. Gobert A, Dekeyne A, Millan MJ (2000). The ability ofWAY100, 635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology 39:1608-1616.
15. Gur E, Lerer B, Dremencov E, Newman ME (2000). Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 11:2925-2929.
16. Gur E, Dremencov E, Garcia F, Van de Kar LD, Lerer B, Newman ME (2002a). Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain Res 952:52-60. (Pubitemid 35279487)
17. Gur E, Lifschytz T, Lerer B, Newman ME (2002b). Effects of triiodothyronine and imipramine on basal 5-HT levels and 5-HT(1) autoreceptor activity in rat cortex. Eur J Pharmacol 457:37-43.
18. Hervas I, Vilaro MT, Romero L, Scorza MC, Mengod G, Artigas F (2001). Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacology 24:11-20.
19. Hong CJ, Chen TJ, Yu YW, Tsai SJ (2006). Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 6:27-33.
20. Hughes ZA, Starr KR, Scott CM, Newson MJ, Sharp T,Watson JM, et al. (2007). Simultaneous blockade of 5-HT(1A/B) receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT(1A/B) receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology (Berl).
21. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. (2000). Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219.
22. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473.
23. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. (2007). Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 61:734-742.
24. Lappalainen J, Dean M, Charbonneau L, Virkkunen M, Linnoila M, Goldman D (1995a). Mapping of the serotonin 5-HT1D beta autoreceptor gene on chromosome 6 and direct analysis for sequence variants. Am J Med Genet 60:157-161.
25. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, et al. (1995b). Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 27:274-279.
26. Lappalainen J, Long JC, Eggert M, Ozaki N, Robin RW, Brown GL, et al. (1998). Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch Gen Psychiatry 55:989-994. (Pubitemid 28506840)
27. Le Francois B, Czesak M, Steubl D, Albert PR (2008). Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55:977-985.
28. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR (2004). Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 7:501-506.
29. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. (2003). Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23:8788-8799.
30. Levitan RD, Kaplan AS, Masellis M, Basile VS,Walker ML, Lipson N, et al. (2001). Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa. Biol Psychiatry 50:640-643.
31. Levitan RD, Kaplan AS, Masellis M, Basile VS, Richter MA, Kennedy JL (2006). The serotonin-1Dbeta receptor gene and severity of obsessive-compulsive disorder in women with bulimia nervosa. Eur Neuropsychopharmacol 16:1-6.
32. Lifschytz T, Gur E, Lerer B, Newman ME (2004). Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: regional differences. J Neurosci Methods 140:133-139.
33. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804-814.
34. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, et al. (2001). Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 303:119-122.
35. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL (2000). Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessivecompulsive disorder? Am J Psychiatry 157:1160-1161.
36. Ozaki N, Lappalainen J, Dean M, Virkkunen M, Linnoila M, Goldman D (1995). Mapping of the serotonin 5-HT1D alpha autoreceptor gene (HTR1D) on chromosome 1 using a silent polymorphism in the coding region. Am J Med Genet 60:162-164.
37. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP (2004). Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 9:879-889.
38. Qin ZS, Niu T, Liu JS (2002). Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71:1242-1247.
39. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, et al. (2002). Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51:723-732.
40. Riad M,Watkins KC, Doucet E, Hamon M, Descarries L (2001). Agonist-induced internalization of serotonin-1a receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors). J Neurosci 21:8378-8386.
41. Rothe C, Gutknecht L, Freitag C, Tauber R, Mossner R, Franke P, et al. (2004). Association of a functional 1019C >G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. Int J Neuropsychopharmacol 7:189-192. (Pubitemid 38823287)
42. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S editors. Bioinformatics methods and protocols: methods in molecular biology. Totowa, New Jersey: Humana Press; (2000). pp. 365-386.
43. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573-583.
44. Sackeim HA (2001). The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62 (Suppl 16):10-17.
45. Sari Y (2004). Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev 28:565-582.
46. Scott C, Soffin EM, Hill M, Atkinson PJ, Langmead CJ, Wren PB, et al. (2006). SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. Eur J Pharmacol 536:54-61.
47. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti A, et al. (2003). A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28:397-401.
48. Sen S, Villafuerte S, Nesse R, Stoltenberg SF, Hopcian J, Gleiberman L, et al. (2004). Serotonin transporter and GABAA alpha 6 receptor variants are associated with neuroticism. Biol Psychiatry 55:244-249.
49. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R (2004). The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 7:453-460.
50. Sharp T, Umbers V, Gartside SE (1997). Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121:941-946.
51. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
52. Starr KR, Price GW,Watson JM, Atkinson PJ, Arban R, Melotto S, et al. (2007). SB-649915-B, a novel 5-HT(1A/B) autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology 10:2163-2172.
53. Strobel A, Gutknecht L, Rothe C, Reif A, Mossner R, Zeng Y, et al. (2003). Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. J Neural Transm 110:1445-1453.
54. The International HapMap Consortium (2007). A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-861.
55. Wu S, Comings DE (1999). A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet 9:105-106.
56. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. (2002). Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386.
57. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115-1119.
58. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ (2006). Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 16:498-503.
59. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107.
60. Zanardi R, Magri L, Rossini D, Malaguti A, Giordani S, Lorenzi C, et al. (2007). Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. Eur Neuropsychopharmacol 17:651-657.